SYED SAQIB: Open Payments
NPI 1619544145 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$538 in 21 payments from 9 companies in 2025. Trend: 2023 $845 · 2024 $209 · 2025 $538
Food & beverage: $538
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 5 | $159 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| AKEBIA THERAPEUTICS INC | 3 | $56 |
| Amgen Inc. | 3 | $55 |
| Novartis Pharmaceuticals Corporation | 3 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: FABRAZYME, JYNARQUE, Vafseo, KRYSTEXXA, Fabhalta, Kerendia, Korlym, AREXVY.
Industry payments across AZ — which companies pay providers there.
